Published 1 Feb 2024

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

Can we operationalize IRTs in real-world clinical practice? The CVD IRT implementation in NHS primary care proves overwhelmingly positive – a significant stride in real-world applicability! IRTs led to substantial reclassification of risk levels, influencing management decisions. Participant perspective in the study also shows high success rates and positive feedback.

In conclusion, the HEART Study showcases the potential of genetic risk assessment in primary care for CVD. A step closer to personalized, effective prevention strategies. For more details, dive into the full study. Let's revolutionize CVD prevention together!